5-MeO-DiBF Stats & Data
COc1ccc2occ(CCN(C(C)C)C(C)C)c2c1NBFMSQBTYHYVKP-UHFFFAOYSA-NReceptor Profile
Receptor Actions
Receptor Binding
Effect Profile
Curated + 4 ReportsStrong visuals, headspace, auditory effects, and body load
Strong sensory enhancement with moderate stimulation, low euphoria
Duration Timeline
BluelightTolerance & Pharmacokinetics
drugs.wikiTolerance Decay
Tolerance guidance is extrapolated from general serotonergic psychedelics and community moderator advice to space trials by ≥1 week; empirical data for 5‑MeO‑DiBF specifically are scarce.
Cross-Tolerances
Experience Report Analysis
ErowidDemographics
Gender Distribution
Age Distribution
Reports Over Time
Effect Analysis
ErowidEffects aggregated from 4 experience reports (4 Erowid)
Effect Sentiment Distribution
Confidence Distribution
Positive Effects 2
Adverse Effects 0
Form / Preparation
Most common forms and preparations reported
Legal Status
| Country | Status | Notes |
|---|---|---|
| Germany | 5-MeO-DiBF is controlled under the NpSG (New Psychoactive Substances Act) as of November 26, 2016. | Production and import with the aim to place it on the market, administration to another person and trading is punishable. Possession is illegal but not penalized. |
| Switzerland | 5-MeO-DiBF is a controlled substance specifically named under Verzeichnis E. | |
| United Kingdom | It is illegal to produce, supply, or import this drug under the Psychoactive Substance Act, which came into effect on May 26th, 2016. |
Harm Reduction
drugs.wiki- Identity and purity: This compound first appeared in EU early warning logs in late 2015; availability has been sporadic and mislabeling within the tryptamine/benzofuran scene is documented. Whenever possible, use an accredited drug checking service; single reagents are not reliable to confirm identity. Avoid assuming it is 5‑MeO‑DiPT or 5‑MeO‑DMT based on name alone.
- Dose variability: Community reports span from threshold activity near 10–20 mg oral to strong effects above 100 mg, suggesting variability in material, salt forms, or individual sensitivity. Treat any new batch as unknown potency and titrate cautiously with a milligram scale and volumetric dosing.
- GI effects: Diarrhoea, stomach cramping, and post‑come‑up headache are frequently reported, especially at higher oral doses. Plan hydration and electrolytes, avoid heavy meals pre-dose, and don’t stack with other GI‑active agents. Persistent vomiting, bloody stools, or severe abdominal pain warrant medical evaluation.
- Restlessness/legs: Akathisia‑like ‘restless legs’ and body jitter are reported at moderate to high doses; avoid stimulants on the day and consider calm, low‑stimulation settings to reduce agitation.
- Insufflation care: The intranasal route has a fast onset and shorter total duration but increases local irritation; limit repeated lines, use isotonic rinses afterward, and allow several days of recovery.
- Redosing: Redosing during the peak tends to increase somatic load more than desirable effects. If chosen at all, wait until effects largely resolve; avoid serial redoses due to unknown pharmacokinetics.
- Spacing: Allow at least 7–14 days between trials to reduce tolerance, confusion of dose–response, and cumulative stress.
- Set/setting and consent: Mild entactogenic and erotic tones are reported by some users; plan boundaries and consent in advance and avoid mixing with alcohol or sedatives that impair judgment.
- Emergencies: Signs of serotonin toxicity (agitation, clonus/tremor, hyperreflexia, hyperthermia) require urgent care. For severe anxiety or dangerous behaviour, a sober sitter and calm environment help; benzodiazepines can abort acute agitation but carry their own risks and should not be pre‑loaded casually.
References
Data Sources
Cited References
- Bluelight: Small & Handy 5-MeO-DiBF thread (2015)
- Bluelight: Pellets & higher-dose reports (2016-2023)
- Drug Users' Bible - 5-MeO-DiBF page
- EMCDDA: Europol Early Warning alert list (2015)
- Erowid: Experience Reports - 5-MeO-DiBF
- PLOS ONE - HR-MS NPS screening (2020)
- Reddit: r/researchchemicals discussion (2015)
- Wikimedia media description - forensic ID (2015)
- HighResNPS consensus fragment ions database
- Turn-in descriptions of 5-MeO-DiBF pellets (Bluelight user BathSalts, 2016)
Drugs.wiki References
- Bluelight — The Small & Handy 5‑MeO‑DIBF thread (2015–)
- Drugs‑Forum trip report (2015): 30–40 mg oral; adverse GI noted; later 60 mg oral + 20 mg insufflated + 110 mg oral
- Reddit r/researchchemicals (2023): multi‑dose oral report incl. diarrhoea, restless legs, headaches; duration timeline
- Drug Users Bible — 5‑MeO‑DIBF monograph (dosage brackets; subjective notes; cautions)
- EMCDDA–Europol 2015 Annual Report — Early warning notification list (5‑MeO‑DIBF first identified, Slovenia, 23 Dec 2015)
- Saferparty.ch warning (2023): 5‑MeO‑DMT mis‑sold as DMT (illustrates mislabeling risk in this family)
- Toronto Drug Checking Service — Tips & Help (why to use drug checking; general harm reduction)